Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jacobson

Showing results (1211-1220 of 1,226) with videos related to

Pageof 123
Sort By:
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2023
Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort StudySuzanne M Ingle, Jose M Miro, Margaret T May, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
JAMA|July 13, 2016
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical TrialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Hepatology (Baltimore, Md.)|November 26, 2008
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsThomas Kuntzen, Joerg Timm, Andrew Berical, et al.
Pageof 123

Showing results (1211-1220 of 1,226) with videos related to

Sort By:
Pageof 123
The Journal of Infectious Diseases|August 8, 2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical StudiesGolnaz Namazi, Jesse M Fajnzylber, Evgenia Aga, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2023
Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort StudySuzanne M Ingle, Jose M Miro, Margaret T May, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
JAMA|July 13, 2016
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical TrialLisa R Metsch, Daniel J Feaster, Lauren Gooden, et al.
Journal of Hepatology|April 23, 2022
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infectionMan-Fung Yuen, Kosh Agarwal, Xiaoli Ma, et al.
Gastroenterology|April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusAlexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Journal of Hepatology|June 13, 2022
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infectionMark S Sulkowski, Kosh Agarwal, Xiaoli Ma, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Hepatology (Baltimore, Md.)|November 26, 2008
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsThomas Kuntzen, Joerg Timm, Andrew Berical, et al.
Pageof 123